Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v5-FR | Version v4-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2020-03-12 | 2020-03-12 |
| Drug Identification Number | 02393581 | 02393581 |
| Brand name | ACT NABILONE | ACT NABILONE |
| Common or Proper name | NABILONE 0.5MG CAPS | NABILONE 0.5MG CAPS |
| Company Name | TEVA CANADA LIMITED | TEVA CANADA LIMITED |
| Ingredients | NABILONE | NABILONE |
| Strength(s) | 0.5MG | 0.5MG |
| Dosage form(s) | CAPSULE | CAPSULE |
| Route of administration | ORAL | ORAL |
| Packaging size | 50 | 50 |
| ATC code | A04AD | A04AD |
| ATC description | ANTIEMETICS AND ANTINAUSEANTS | ANTIEMETICS AND ANTINAUSEANTS |
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | ||
| Actual start date | 2019-12-18 | 2019-12-18 |
| Estimated end date | ||
| Actual end date | 2020-03-11 | 2020-03-11 |
| Shortage status | Resolved | Resolved |
| Tier 3 Status | No | No |
| Company comments | Item is to be discontinued, and transitioned to the TEVA DIN | Item is to be discontinued, and transitioned to the TEVA DIN |
| Health Canada comments |